Clinical Trial Update: Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating secukinumab in rheumatoid arthritis patients with inadequate response to anti-TNF therapy assessed efficacy at 24 weeks and examined sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2016-05-23